Form 4: Bio-Rad Laboratories Director, Melinda Litherland Pei, Reports Stock Transactions

Director Melinda Litherland Pei reports acquisition of Bio-Rad Laboratories Class A common stock through vesting of restricted stock units.

Summary

• On April 22, 2025, Melinda Litherland Pei, a director of Bio-Rad Laboratories, reported transactions involving Bio-Rad Class A common stock.
• She acquired 308 shares of Class A common stock upon the vesting of restricted stock units at a price of $0.
• Additionally, she was granted 407 restricted stock units that will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.
• She also had 308 restricted stock units vest on April 22, 2025, which were originally granted on September 6, 2024.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment.

Positives

• The vesting of restricted stock units indicates a continued alignment of the director's interests with those of the shareholders.

Future Outlook

The restricted stock units will vest 100% on the earlier of the first anniversary of the grant date or the date of the company's next annual meeting of stockholders.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard compensation practices for board members.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they represent routine compensation-related stock activity.

Key Dates

Keywords

Form 4, Beneficial Ownership, BIO, BIO.B, Bio-Rad Laboratories, Melinda Litherland Pei, Director, Restricted Stock Units, Stock Transaction